The global nutraceutical contract manufacturing services market size is calculated at USD 167.64 billion in 2024, grew to USD 187.92 billion in 2025, and is predicted to hit around USD 525.32 billion by 2034, poised to grow at a CAGR of 12.1% between 2024 and 2034. The North America nutraceutical contract manufacturing services market size accounted for USD 58.67 billion in 2024 and is anticipated to grow at the fastest CAGR of 12.25% during the forecast year.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Nutraceutical Contract Manufacturing Services Market
5.1. COVID-19 Landscape: Nutraceutical Contract Manufacturing Services Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Nutraceutical Contract Manufacturing Services Market, By Product
8.1. Nutraceutical Contract Manufacturing Services Market, by Product Type, 2024-2034
8.1.1. Dietary Supplements
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Functional Food and Beverages
8.1.2.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Nutraceutical Contract Manufacturing Services Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, by Product (2021-2034)
9.1.2. U.S.
9.1.2.1. Market Revenue and Forecast, by Product (2021-2034)
9.1.3. Rest of North America
9.1.3.1. Market Revenue and Forecast, by Product (2021-2034)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Product (2021-2034)
9.2.2. UK
9.2.2.1. Market Revenue and Forecast, by Product (2021-2034)
9.2.3. Germany
9.2.3.1. Market Revenue and Forecast, by Product (2021-2034)
9.2.4. France
9.2.4.1. Market Revenue and Forecast, by Product (2021-2034)
9.2.5. Rest of Europe
9.2.5.1. Market Revenue and Forecast, by Product (2021-2034)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Product (2021-2034)
9.3.2. India
9.3.2.1. Market Revenue and Forecast, by Product (2021-2034)
9.3.3. China
9.3.3.1. Market Revenue and Forecast, by Product (2021-2034)
9.3.4. Japan
9.3.4.1. Market Revenue and Forecast, by Product (2021-2034)
9.3.5. Rest of APAC
9.3.5.1. Market Revenue and Forecast, by Product (2021-2034)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Product (2021-2034)
9.4.2. GCC
9.4.2.1. Market Revenue and Forecast, by Product (2021-2034)
9.4.3. North Africa
9.4.3.1. Market Revenue and Forecast, by Product (2021-2034)
9.4.4. South Africa
9.4.4.1. Market Revenue and Forecast, by Product (2021-2034)
9.4.5. Rest of MEA
9.4.5.1. Market Revenue and Forecast, by Product (2021-2034)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Product (2021-2034)
9.5.2. Brazil
9.5.2.1. Market Revenue and Forecast, by Product (2021-2034)
9.5.3. Rest of LATAM
9.5.3.1. Market Revenue and Forecast, by Product (2021-2034)
Chapter 10. Company Profiles
10.1. Catalent, Inc.
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Lonza Group AG
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Royal DSM N.V.
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Glanbia plc
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Capsugel (A Lonza Company)
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Patheon, now part of Thermo Fisher Scientific
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Nature's Bounty Co.
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. Nutrascience Labs
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. Vitakem Nutraceutical Inc.
10.9.1. Company Overview
10.9.2. Product Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. Paragon Laboratories
10.10.1. Company Overview
10.10.2. Product Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
12.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample